Key Efficacy Results From ADVANCE: MRD Negativity Stratified by Age and Risk
Panelists discuss how ADVANCE results show daratumumab-based quadruplets achieve high MRD negativity across risk and age groups in NDMM.
EP: 1.Review of Latest Guidelines on Quad Therapy in NDMM
EP: 2.Classifying High-Risk Patients With NDMM
EP: 3.Pretesting Prior to Quad Therapy for NDMM
EP: 4.Overview of the ADVANCE Study: Methodology and Design
EP: 5.Expert Perspectives on the Design of the ADVANCE Trial
EP: 6.Key Efficacy Results From ADVANCE: MRD Negativity Stratified by Age and Risk
Panelists discuss how the ADVANCE study findings demonstrated high rates of minimal residual disease (MRD) negativity across both standard- and high-risk groups, reinforcing the potential of daratumumab-containing quadruplets to overcome adverse prognostic features. They highlight that MRD negativity correlated strongly with improved progression-free survival across age cohorts. The discussion notes that older patients also benefited, showing that advanced age alone should not preclude intensive therapy when performance status allows. The data suggest a meaningful narrowing of efficacy gaps between risk categories, supporting continued use of MRD as a dynamic end point for therapy adjustment.
